Please login to the form below
respiratory syncytial virus
This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.
AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial
Drug reduced lower respiratory tract infections caused by respiratory syncytial virus in infants. ... AstraZeneca (AZ) and Sanofi’s long-acting antibody nirsevimab met the primary endpoint in a late-stage respiratory syncytial virus (RSV) trial in
Latest news
-
GSK launches late-stage testing of RSV vaccine candidate in older adults
GlaxoSmithKline (GSK) has launched a phase 3 trial investigating its respiratory syncytial virus (RSV) vaccine candidate in older adults.
-
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
restore the lung’s immune response and accelerate recovery from COVID-19,” said Tom Wilkinson, professor of respiratory medicine at the University of Southampton and lead author of the study. ... This might carry additional advantages of treating
-
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
The trial included participants with a range of common respiratory virus infections, including rhinovirus, influenza, adenovirus, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza and coronavirus – although not the
-
Roche plans to launch rapid COVID-19 antigen test later this month
The rapid test can identify the presence of SARS-CoV-2 infection, which causes COVID-19, in people suspected to carry the virus in as little as 15 minutes. ... The Winterplex test includes two gene targets specific to COVID-19, as well as gene targets
-
Novacyt launches diagnostic test to differentiate between COVID-19 and flu
The clinical diagnostics company said that its Winterplex test includes two gene targets specific to COVID-19, as well as gene targets for influenza A and B and respiratory syncytial virus ... This means that PCR tests can tell whether someone has the
GSK launches late-stage testing of RSV vaccine candidate in older adults
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
Roche plans to launch rapid COVID-19 antigen test later this month
Novacyt launches diagnostic test to differentiate between COVID-19 and flu
More from news
Approximately 2 fully matching, plus 39 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)
-
COVID-19: the race to find a vaccine
In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.
-
Getting multichannel marketing right
has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.
-
Deal Watch March 2017
In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.
-
Pharma deals during September 2014
Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.
Well-funded life sciences firms are making long-term progress – and their investors are too
COVID-19: the race to find a vaccine
Getting multichannel marketing right
Deal Watch March 2017
Pharma deals during September 2014
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.
Dutch biotech Mucosis promotes Thomas Johnston to CEO
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Executive
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Senior Medical Writer
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Medical Editor
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
-
Publications Director
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
